Renal Dialysis Clinical Trial
Official title:
Citrasate® Effect On Heparin N Requirements During Hemodialysis Treatment: A Phase IV,Study to Investigate the Effects of Citrasate on Heparin N Requirements During Hemodialysis Treatment in Subjects Maintained on Thrice Weekly Hemodialysis
The purpose of this study is to determine whether the use of Citrasate®, citric acid dialysate enables the reduction of the heparin N (anticoagulant) dose in patients undergoing hemodialysis.
During hemodialysis, waste products are removed from the blood by diffusion across the dialyzer membrane into an electrolyte solution known as dialysate. Dialysate is produced from acid concentrate, bicarbonate solution and water using a three stream proportioning system that mixes the acid concentrate, bicarbonate and water to produce the final dialysate. Patients are typically anticoagulated with heparin during dialysis to prevent blood from clotting in the extracorpoeial circuit. Heparin use is associated with significant risks including the possibility of bleeding, heparin induced thrombocytopenia (HIT) and contamination. For these reasons, the possibility of reducing heparin dose while maintaining HD adequacy is clinically attractive. Citrasate® is an FDA approved acid concentrate that contains citric acid (citrate) rather than acetic acid (acetate) which is traditionally used in acid concentrate. Citrate in higher concentrations is also a known anticoagulant. We are therefore conducting this study to determine whether the use of Citrasate, citric acid dialysate enables the reduction of the heparin requirements in patients undergoing hemodialysis. ;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05189795 -
The Construction of Physical ACtivity Enhancement Scheme (PACES) in Hemodialysis Patients
|
||
Completed |
NCT01125202 -
Intervention to Reduce Dietary Sodium in Hemodialysis
|
N/A | |
Completed |
NCT00753116 -
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
|
Phase 1 | |
Completed |
NCT00730145 -
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
|
Phase 1 | |
Completed |
NCT00806130 -
Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients
|
||
Completed |
NCT05718765 -
The Effect of Physical ACtivity Enhancement Scheme (PACES) in Hemodialysis Patients
|
N/A | |
Completed |
NCT03250715 -
Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure
|
N/A | |
Completed |
NCT05469620 -
Adaptive Nutrition Therapy in Hemodialysis
|
N/A | |
Completed |
NCT03536858 -
Social Networks and Renal Education: Promoting Transplantation
|
N/A | |
Completed |
NCT00824837 -
Study of beta2-Microglobulin Removal by Standard Versus New High Cut-Off Haemodialysis Membrane
|
Phase 1/Phase 2 | |
Completed |
NCT03403491 -
Study of Self-monitoring of Weight & Blood Pressure (Via patientMpower Platform) in Hemodialysis
|
N/A | |
Terminated |
NCT02495662 -
The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation
|
Phase 2 | |
Completed |
NCT01179620 -
Certoparin in Renal Patients Undergoing Hemodialysis
|
Phase 3 | |
Completed |
NCT01017276 -
A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
|
Phase 3 | |
Active, not recruiting |
NCT04466865 -
A Communication Tool to Assist Older Adults Facing Dialysis Choices
|
N/A | |
Recruiting |
NCT03782519 -
Quality of Life of Frail Aged Patients in Incremental Hemodialysis
|
N/A | |
Recruiting |
NCT02843334 -
Study of the Prevalence of Fabry Disease in French Dialysis Patients
|
N/A | |
Recruiting |
NCT02545530 -
Transdermal Clonidine in Chronic Hemodialysis Patients
|
N/A | |
Completed |
NCT00892749 -
Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
|
Phase 3 | |
Completed |
NCT00649298 -
A Clinical Trial of IntensiVE Dialysis
|
Phase 4 |